Detail page

Knowledge Web

Person

Tim Hagenacker (1981-)

Arzt

Name	Tim Hagenacker
Time	1981- (Date of birth and death)
Place	Oberhausen (Geburtsort) Deutschland
Gender	männlich
Academic degree	Dr. med.
Profession	Arzt (characteristic profession)
Related	Universitätsklinikum Essen
Further information	Facharzt für Neurologie, Privatdozent Leitender Oberarzt in der "Klinik für Neurologie" am Universitätsklinikum Essen
Source	Homepage: https://neurologie.uk-essen.de/ueber-uns/mitarbeiter/klinikleitung/ (Gesehen am 21.04.2020)
Record type	Person
GND-Identifier	138906262
Record ID	138906262
Involved in show all Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry Konsilfrage „Amyloidose“ – und jetzt? Nützliches Hintergrundwissen zur Diagnostik und Therapie in der Neurologie The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular Atrophy Oral function tests in spinal muscular atrophy: closing the diagnostic gap in severely affected adult patients : A prospective observational study Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS) Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival Eplontersen (Wainzua®) bei hereditärer Transthyretin-Amyloidose mit Polyneuropathie (ATTRv-PN) Iatrogenic botulism after intragastric botulinum neurotoxin injections – a major outbreak Oral functions in adult persons with spinal muscular atrophy compared to a healthy control group: a prospective cross-sectional study with a multimodal approach Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis Patients’ and caregivers’ perception of multidimensional and palliative care in amyotrophic lateral sclerosis – protocol of a German multicentre study Fatigue and associated factors in myasthenia gravis: a nationwide registry study Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy 5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2 Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment Health-related quality of life in spinal muscular atrophy patients and their caregivers — a prospective, cross-sectional, multi-center analysis Iatrogenic botulism after intragastric botulinum neurotoxin injections - a major outbreak Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study Patients’ and caregivers’ perception of multidimensional and palliative care in amyotrophic lateral sclerosis – protocol of a German multicentre study Transcriptomic profiling of the hippocampus and frontal cortex in the context of cognitive dysfunction in mouse models of Spinal Muscular Atrophy and Parkinson's disease Versorgung von Patienten mit kardialer Amyloidose : Konsensuspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), AG 40 Onkologische Kardiologie, und der Deutschen Gesellschaft für Hämatologie und medizinische Onkologie e. V. (DGHO), der Deutschen Gesellschaft für Neurologie e. V. (DGN) und der Deutschen Gesellschaft für Nephrologie e. V. (DGfN) Benign peripheral nerve sheath tumors: an interdisciplinary diagnostic and therapeutic challenge Economic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany Brainstem Infarction in Immunodeficiency Identified as Adenosine Deaminase 2 Deficiency: Case Report Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis Spinal astrocyte dysfunction drives motor neuron loss in late-onset spinal muscular atrophy Astrozyten-vermittelte Glutamat-Toxizität bei der Spinalen Muskelatrophie Behandlungsstrategien bei 5q-SMA im Kindes- und Erwachsenenalter: fallbasierte Überlegungen und Orientierungshilfen für die Praxis Closing the Gap - Detection of 5q-Spinal Muscular Atrophy by Short-Read Next-Generation Sequencing and Unexpected Results in a Diagnostic Patient Cohort Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis Therapie und Verlauf neurologischer Erkrankungen ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report Radiation dose and fluoroscopy time of aneurysm coiling in patients with unruptured and ruptured intracranial aneurysms as a function of aneurysm size, location, and patient age Correction to: Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis Essen transition model for neuromuscular diseases Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients „Essener Transitionsmodell“ bei neuromuskulären Erkrankungen Neurofilament als Biomarker und zum Monitoring der Therapie von spinaler Muskelatrophie? Behandlungseffekt evaluieren anhand der Bulbärfunktion Erkrankungsmarker für das Therapiemonitoring EMBRACE bestätigt längerfristige Sicherheit und Verträglichkeit von Nusinersen Therapieerfolg: Einmalige Genersatztherapie könnte lebenslang wirken Orale Therapie der SMA mit Spleißmodulator Risdiplam Eculizumab versus rituximab in generalised myasthenia gravis Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients Induction of Survival of Motor Neuron (SMN) Protein Deficiency in Spinal Astrocytes by Small Interfering RNA as an In Vitro Model of Spinal Muscular Atrophy Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Tim Hagenacker (1981-)

Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry

Konsilfrage „Amyloidose“ – und jetzt? Nützliches Hintergrundwissen zur Diagnostik und Therapie in der Neurologie

The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study

Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient

Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular Atrophy

Oral function tests in spinal muscular atrophy: closing the diagnostic gap in severely affected adult patients : A prospective observational study

Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS)

Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival

Eplontersen (Wainzua®) bei hereditärer Transthyretin-Amyloidose mit Polyneuropathie (ATTRv-PN)

Iatrogenic botulism after intragastric botulinum neurotoxin injections – a major outbreak

Oral functions in adult persons with spinal muscular atrophy compared to a healthy control group: a prospective cross-sectional study with a multimodal approach

Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy

Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis

Patients’ and caregivers’ perception of multidimensional and palliative care in amyotrophic lateral sclerosis – protocol of a German multicentre study

Fatigue and associated factors in myasthenia gravis: a nationwide registry study

Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment

Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison

Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy

5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2

Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment

Health-related quality of life in spinal muscular atrophy patients and their caregivers — a prospective, cross-sectional, multi-center analysis

Iatrogenic botulism after intragastric botulinum neurotoxin injections - a major outbreak

Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study

Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study

Patients’ and caregivers’ perception of multidimensional and palliative care in amyotrophic lateral sclerosis – protocol of a German multicentre study

Transcriptomic profiling of the hippocampus and frontal cortex in the context of cognitive dysfunction in mouse models of Spinal Muscular Atrophy and Parkinson's disease

Benign peripheral nerve sheath tumors: an interdisciplinary diagnostic and therapeutic challenge

Economic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany

Brainstem Infarction in Immunodeficiency Identified as Adenosine Deaminase 2 Deficiency: Case Report

Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis

Spinal astrocyte dysfunction drives motor neuron loss in late-onset spinal muscular atrophy

Astrozyten-vermittelte Glutamat-Toxizität bei der Spinalen Muskelatrophie

Behandlungsstrategien bei 5q-SMA im Kindes- und Erwachsenenalter: fallbasierte Überlegungen und Orientierungshilfen für die Praxis

Closing the Gap - Detection of 5q-Spinal Muscular Atrophy by Short-Read Next-Generation Sequencing and Unexpected Results in a Diagnostic Patient Cohort

Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy

Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study

Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis

Therapie und Verlauf neurologischer Erkrankungen

ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale

A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report

Radiation dose and fluoroscopy time of aneurysm coiling in patients with unruptured and ruptured intracranial aneurysms as a function of aneurysm size, location, and patient age

Correction to: Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany

Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study

Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis

Essen transition model for neuromuscular diseases

Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany

Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

„Essener Transitionsmodell“ bei neuromuskulären Erkrankungen

Neurofilament als Biomarker und zum Monitoring der Therapie von spinaler Muskelatrophie?

Behandlungseffekt evaluieren anhand der Bulbärfunktion

Erkrankungsmarker für das Therapiemonitoring

EMBRACE bestätigt längerfristige Sicherheit und Verträglichkeit von Nusinersen

Therapieerfolg: Einmalige Genersatztherapie könnte lebenslang wirken

Orale Therapie der SMA mit Spleißmodulator Risdiplam

Eculizumab versus rituximab in generalised myasthenia gravis

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

Induction of Survival of Motor Neuron (SMN) Protein Deficiency in Spinal Astrocytes by Small Interfering RNA as an In Vitro Model of Spinal Muscular Atrophy

Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany